Please login to the form below

Not currently logged in
Email:
Password:

OSE Immunotherapeutics

This page shows the latest OSE Immunotherapeutics news and features for those working in and with pharma, biotech and healthcare.

China’s Innovent to start US trials of anti-CD47 cancer drug

China’s Innovent to start US trials of anti-CD47 cancer drug

And earlier this year Boehringer Ingelheim licensed a drug from French biotech OSE Immunotherapeutics that targets SIRP-alpha – which binds to CD47 – in a 1.1bn deal.

Latest news

  • Boehringer bolts on another immuno-oncology company Boehringer bolts on another immuno-oncology company

    ViraTherapeutics is just one a of a series of investments Boehringer has made in immuno-oncology, coming after a 1.1bn deal to license a checkpoint inhibitor from French biotech OSE ... Immunotherapeutics and earlier alliances with Siamab, AbeXXa

  • Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

    Boehringer Ingelheim has licensed a new checkpoint inhibitor from French biotech OSE Immunotherapeutics in a deal that could be worth more than 1.1bn (around $1.4bn). ... The deal focuses around OSE-172, an anti-SIRP-alpha antibody with potential in

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    She becomes clinical project director at the French biotech. Nantes, France-based biotech OSE Immunotherapeutics has bolstered its clinical team with the appointment of Iris Pauporté as clinical project director. ... Alain Chatelin, medical director at

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics